FOERFARANDE Foer FRAMSTAELLNING AV EN TOPISK, Farmaceutisk BEREDNING Foer PAOSKYNDANDE AV SAORGRANULATION OCH EPITELISATION.

摘要

for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE 1. A topical pharmaceutical preparation for the promotion of granulation and epithelization of wounds, containing a pharmacologically compatible carrier and an active substance, characterized by the fact that the carrier mainly consists of water or occurs in the form of a hydrated gel or as a dry gel and that the active substance increases the calcium-permeability of the plasma membrane and comprises either a) an ionizable mixture of pharmacologically compatible Ca**2+ and K**+ salts wherein, the Ca**2+ ions in the carrier occur at a concentration of 20 to 100 mM in relation to the water contained therein and the K**+-ions at a concentration of 25 to 60 mM ; or b) a Ca**2+-ionophore at a concentration of 3 x 10**-8 to 3 x 10**-6 M in combination with calcium salts at a concentration of 0.1 to 50 mM ; or c) a calcium-agonist at a concentration of 10**-5 to 10**-9 M in the presence of K**+-ions at a concentration of 5 x 10**-3 to 2 x 10**-2 M and Ca**2+ at a concentration of 10**-3 M to 3 x 10**-2 M. for the Contracting State AT 1. Process for the manufacture of a topical pharmacentical preparation for the promotion of the granulation and epithelization of wounds, containing a pharmacologically compatible carrier and an active substance, characterized by the fact that the carrier consists mainly of water or occurs in the form of a hydrated gel or as a dry gel and that the active substance increases the calcium-permeability of the plasma membrane and comprises either a) an ionizable mixture of pharmacologically compatible Ca**2+ and K**+ salts, wherein the Ca**2+ ions in the carrier occur at a concentration of 20 to 100 mM in relation to the water contained therein and the K**+ ions at a concentration of 25 to 60 mM ; or b) a Ca**2+-ionophore at a concentration of 3 x 10**-8 to 3 x 10**-6 M in combination with calcium salts at a concentration of 0.1 to 50 mM ; or c) a calcium-agonist at a concentration of 10**-5 to 10**-9 M in the presence of K**+-ions at a concentration of 5 x 10**-3 to 2 x 10**-2 M and Ca**2+ at a concentration of 10**-3 M to 3 x 10**-2 M ; and that in a pharmacologically compatible carrier, optionally in addition to other active substances and/or excipients, there is uniformly distributed an active substance a), b) or c).